The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Subscribe To Our Newsletter & Stay Updated
